Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/8/18 → 11/8/20 |
Funding
- Vertex Pharmaceuticals Incorporated: $11,694.00
A Post-approval Observational Study to Evaluate the Long-term Effectiveness and Safety of Orkambi in US Patients Who completed Study VX12-8090-105 Part A
- Frederick, Carla (PI)
- Goetz, Danielle (CoI)
Project: Research